What Levostrel Treats: Main Uses and Benefits

Levostrel is considered relevant within Emergency Reproductive Health. It assists with managing the risk of unintended pregnancy. The medication is generally applied in addressing risk following unprotected sexual intercourse or scenarios where the integrity of routine contraceptive methods is compromised. It is used for post-coital pregnancy prevention.

The medication contributes to easing the overall symptom load by offering a specialized intervention option when additional assistance is needed to manage the potential consequences of an unexpected high-risk event. This supportive measure helps reduce the risk of conception and assists with managing the discomfort associated with a compromised contraceptive status.

“The therapeutic goal is intervention following specific high-risk events, providing a medically recognized option for acute risk management.”

---

Quick Fact: Relevant for Acute Contraceptive Risk

Use Context	Benefit Provided	Patient Group
Contraceptive Failure	Supports risk mitigation	Women of childbearing potential
Unprotected Intercourse	Assists with acute support	Postpubertal adolescents

---

Levostrel is commonly used as an acute, non-routine measure. It supports general well-being during symptomatic phases where uncertainty may be present. It is applied in addressing the acute risk associated with a compromised contraceptive status.

Eligibility Scope

Category	Regulatory Status
Allowed Population	Females of childbearing potential (post-menarcheal).
Contraindicated	Patients with known or suspected pregnancy.
Contraindicated	Patients with a known allergy or hypersensitivity to levonorgestrel or any excipients.
Not Recommended	Patients with severe hepatic dysfunction (severe liver impairment).
Use Restricted	Patients using certain enzyme-inducing medicines (e.g., St. John's Wort) due to potential reduced efficacy.

Levostrel is intended exclusively for use by post-menarcheal women, and its use is not indicated in premenarcheal children or postmenopausal women. The official regulatory classification states that the medicine is contraindicated if a woman is already pregnant, as it is ineffective in terminating an existing pregnancy.

Regulatory documents highlight conditions for restricted use. Caution is advised for women with a history of ectopic pregnancy or salpingitis, though this is not an absolute prohibition. Use in patients with severe malabsorption syndromes or rare hereditary conditions like total lactase deficiency is also restricted. For breastfeeding women, levonorgestrel is generally deemed acceptable, but a brief interruption in nursing (e.g., 8 hours after the dose) is noted by some regulators to minimize infant exposure.

Interactions with other medicines and products

The official regulatory profile for Levostrel is defined by pharmacokinetic interactions that may lead to a reduction in efficacy. This effect is primarily caused by Hepatic Enzyme Inducers, specifically those that enhance the activity of Cytochrome P450 3A4 (CYP3A4) enzymes.

The co-administration of these substances enhances the metabolism of levonorgestrel, resulting in a documented decrease in its plasma concentrations and overall exposure. This reduced systemic exposure is the direct cause of the potential decreased effectiveness of the medicine.

Medicinal Products and Substances Documented to Interact:

Category	Specific Medicines and Substances
Anticonvulsants	Phenytoin, Carbamazepine, Phenobarbital, Primidone, Oxcarbazepine
Antibacterials/Antivirals	Rifampin, Griseofulvin, Efavirenz, HIV Protease Inhibitors
Herbal Products	St. John's wort (Hypericum perforatum)
Other	Bosentan

The interaction is classified as clinically significant due to the potential for therapeutic failure. Regulatory authorities acknowledge this interaction by stating that the use of Levostrel in individuals who have recently used these enzyme-inducing medicines requires a specific management approach to mitigate the risk of therapeutic failure. This constitutes the central constraint on co-administration noted in official prescribing information.

Modulation of the Central Hormonal Axis

The primary mechanism of action involves Levonorgestrel acting as an agonist at the Progesterone Receptor (PR) within the central neuroendocrine structures. By engaging these receptors, the drug suppresses the hormonal signaling necessary to trigger the Luteinizing Hormone (LH) surge. This sequence prevents the final stage of follicular rupture, resulting in the inhibition of ovulation .

---

Local Alteration of Cervical Mucus

A distinct, parallel mechanism is observed at the peripheral level in the cervix. Levonorgestrel also modulates the Progesterone Receptors in the cervical tissue, which alters the physical and chemical composition of the secreted mucus. This local action transforms the normally receptive cervical mucus into a thick, dense, and viscous plug, creating a physical barrier that restricts sperm motility and migration.

---

Mechanistic Limitations

The inhibitory effect on the LH surge is ineffective if ovulation has already begun or completed. The mechanistic action is directed toward preventing fertilization; it does not include a known mechanism for altering implantation.

How to Use Levostrel: Official Administration Guidelines

Levostrel (levonorgestrel) is structured for acute, single-event use only and is administered via the oral route as a tablet. Its use is defined by a strict time-critical window and specific established dosing regimens.

---

Dosing and Schedule

Levostrel must be taken as soon as possible after unprotected sexual intercourse or known contraceptive failure. The administration window closes at 72 hours (three days) following the event.

Official regimens include the single-dose and two-dose methods:

Regimen	Dose Strength	Schedule
Single-Dose	1.5 mg (one tablet)	Taken as a single, one-time dose.
Two-Dose	0.75 mg (two tablets)	First dose taken immediately; the second 0.75 mg dose taken 12 hours later.

---

Administration Context and Adjustments

Usage can occur at any time during the menstrual cycle. No specific instructions are provided regarding administration with or without food.

Instructions exist for specific scenarios:

• Vomiting Protocol: If the tablet is expelled through vomiting within 3 hours of taking it, a repeat dose is advised immediately to ensure the medicine is retained.
• Enzyme-Inducing Drugs: For women taking certain hepatic enzyme-inducing drugs, a double dose (total 3 mg) may be indicated if a non-hormonal option is unavailable.
• Post-Treatment: Levostrel is not intended for continuous use. Following administration, routine contraception should be continued or initiated immediately.

The structure of these instructions emphasizes time-critical action and proper dose retention, establishing a distinct, non-routine protocol for its use.

Foundational Research Structure on Levostrel (Levonorgestrel)

The research on Levostrel was structured around large-scale Randomized Controlled Trials (RCTs) and systematic reviews that synthesize these findings. Researchers carefully measured the observed number of pregnancies and compared it to the expected number of pregnancies that would have occurred without any administered study medication. This comparison, often called the "Prevented Fraction," is the primary metric studies use to evaluate the observed outcomes. The majority of this foundational research focused on participants who received the study medication within 72 hours of unprotected sexual intercourse.

Some studies monitored physiologic patterns in the body, observing how the medication relates to physiological markers, such as the timing of the LH surge. These findings describe the physiological changes monitored during the study period and contribute to the broader evidence landscape.

Evidence Assessment for use in Acute Pregnancy Risk Management

The research dedicated to the core use of Levostrel involves comparing its outcomes to older emergency contraceptive options or to other newer options. These studies were conducted on women who participated in research after unprotected sexual intercourse or documented contraceptive failure.

Research showed a pattern where the observed pregnancy rate increased as the time interval between the unprotected event and administration lengthened. Studies explored the relationship between promptness of administration and the measured outcomes. Some research observed a pattern where administration before the Luteinizing Hormone (LH) surge was associated with an altered pattern of follicular development.

Studies in Special Populations

Specific research has explored outcomes in distinct populations, particularly those related to body weight and Body Mass Index (BMI). Pooled analyses from major clinical trials described a pattern where the rate of pregnancy was higher in cohorts with increased BMI compared to participants with a normal BMI. However, the findings in this area were mixed. Other large analyses did not find evidence robust enough to definitively link observed outcomes to increased body weight. The research also included studies that evaluated outcomes in adolescent age groups.

Long-Term Observation and Follow-up Research

The primary focus of most clinical trials was on short-term follow-up, which included participant contact five to seven days after the expected date of menstruation for the purpose of pregnancy evaluation.

Research has also provided context on long-term outcomes in cases where pregnancies occurred. Prospective cohort studies have monitored children born in these specific situations, observing outcomes related to physical growth and mental development over a two-year period. These studies monitor children born in these specific situations, though follow-up durations were limited.

Research Gaps and Uncertainties

Research highlights what is known and what is still uncertain about Levostrel. One key limitation is that the observed rates change based on the length of time from unprotected intercourse. Comparative data remains limited, and sample sizes were modest for studies that examined administration beyond the 72-hour mark (up to 120 hours). Additionally, data are also still emerging regarding the effectiveness profile of repeated use of the medication within the same menstrual cycle. Existing studies provide limited insight into whether the intervention has an effect if administered after the ovulation process has already been initiated.

Key Studies & References

1. Levonorgestrel - StatPearls (NIH) Summary (General background, time sensitivity, regulatory context)

How to Store and Dispose of Levostrel?

Levostrel (levonorgestrel tablet) requires strict adherence to documented storage and disposal rules to maintain product stability and safety.

Storage Requirements

The product must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). Brief excursions outside this range are permitted up to 30 C (86 F). The tablet must be stored in the original package and protected from light to maintain quality. Do not use the medicine if the blister seal is broken or missing. Furthermore, all tablets must be kept out of the sight and reach of children.

Disposal

Official regulatory documents require that any unused medicinal product or waste material be disposed of in accordance with local requirements for pharmaceutical waste.